Annals of Oncology

1

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., Kefford, R. F., Carlino, M. S., Rizos, H.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.38 MB

english, 2017

2

The role of AR polyQ tract in male breast carcinoma: lesson from an SBMA case

Querin, G., Martinelli, I., Bertolin, C., Pegoraro, E., Pennuto, M., Sorarù, G.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 192 KB

english, 2017

3

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial

Lesurf, R., Griffith, O. L., Griffith, M., Hundal, J., Trani, L., Watson, M. A., Aft, R., Ellis, M. J., Ota, D., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Boughey, J. C., Unzeitig, G., Buzdar,

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 338 KB

english, 2017

4

CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification

Pilati, C., Taieb, J., Balogoun, R., Marisa, L., de Reyniès, A., Laurent-Puig, P.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.02 MB

english, 2017

5

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

Besse, B., Mazières, J., Ribassin-Majed, L., Barlesi, F., Bennouna, J., Gervais, R., Moreau, L., Berard, H., Debieuvre, D., Molinier, O., Moro-Sibilot, D., Souquet, P. J., Jacquot, S., Petit, L., Lena

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.70 MB

english, 2017

6

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

Petrella, T., Copie-Bergman, C., Brière, J., Delarue, R., Jardin, F., Ruminy, P., Thieblemont, C., Figeac, M., Canioni, D., Feugier, P., Fabiani, B., Leroy, K., Parrens, M., André, M., Haioun, C., Sal

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 4.45 MB

english, 2017

7

Data resources for the identification and interpretation of actionable mutations by clinicians

Prawira, A., Pugh, T. J., Stockley, T. L., Siu, L. L.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.12 MB

english, 2017

8

Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma

Teckie, S., Qi, S., Chelius, M., Lovie, S., Hsu, M., Noy, A., Portlock, C., Yahalom, J.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.46 MB

english, 2017

9

Modeling individual and relative accuracy of screening tools in geriatric oncology

Bellera, C. A., Artaud, F., Rainfray, M., Soubeyran, P. L., Mathoulin-Pélissier, S.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 2.04 MB

english, 2017

10

Intratumoral heterogeneity in gastric cancer: a new challenge to face

Alsina, M., Gullo, I., Carneiro, F.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 183 KB

english, 2017

11

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

Gopal, A. K., Fanale, M. A., Moskowitz, C. H., Shustov, A. R., Mitra, S., Ye, W., Younes, A., Moskowitz, A. J.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 725 KB

english, 2017

12

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

Dienstmann, R., Mason, M. J., Sinicrope, F. A., Phipps, A. I., Tejpar, S., Nesbakken, A., Danielsen, S. A., Sveen, A., Buchanan, D. D., Clendenning, M., Rosty, C., Bot, B., Alberts, S. R., Milburn Jes

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.35 MB

english, 2017

13

Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma

Balagué, O., Campo, E.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 212 KB

english, 2017

14

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator,

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.02 MB

english, 2017

15

European cancer mortality predictions for the year 2017, with focus on lung cancer

Malvezzi, M., Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., La Vecchia, C., Negri, E.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 508 KB

english, 2017

16

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

Guberina, M., Eberhardt, W., Stuschke, M., Gauler, T., Heinzelmann, F., Cheufou, D., Kimmich, M., Friedel, G., Schmidberger, H., Darwiche, K., Jendrossek, V., Schuler, M., Stamatis, G., Pöttgen, C.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 895 KB

english, 2017

17

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Tam, C. S., Seymour, J. F.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 183 KB

english, 2017

18

PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?

Vlachostergios, P. J., Molina, A. M.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 251 KB

english, 2017

19

Immunotherapy and epithelial ovarian cancer: a double-edged sword?

Ray-Coquard, I., Lorusso, D.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 183 KB

english, 2017

20

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer

Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Murgioni, S., Rossini, D., Marmorino, F., Mennitto, A., Ning, Y., Okazaki, S., Berger, M. D., Miyamoto, Y., Gopez, R., Barzi, A., Yamaguchi, T

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 521 KB

english, 2017

21

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Monk, B. J., Brady, M. F., Aghajanian, C., Lankes, H. A., Rizack, T., Leach, J., Fowler, J. M., Higgins, R., Hanjani, P., Morgan, M., Edwards, R., Bradley, W., Kolevska, T., Foukas, P., Swisher, E. M.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 785 KB

english, 2017

22

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape

Vis, D. J., Lewin, J., Liao, R. G., Mao, M., Andre, F., Ward, R. L., Calvo, F., Teh, B. T., Camargo, A. A., Knoppers, B. M., Sawyers, C. L., Wessels, L. F. A., Lawler, M., Siu, L. L., Voest, E.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 1.32 MB

english, 2017

23

HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma

Chen, X., Gao, L., Sturgis, E. M., Liang, Z., Zhu, Y., Xia, X., Zhu, X., Chen, X., Li, G., Gao, Z.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 119 KB

english, 2017

24

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Sartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., Xu, L., Shan, M., Kattan, M. W., Parker, C.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 298 KB

english, 2017

25

Subjective and objective taste and smell changes in cancer

Spotten, L. E., Corish, C. A., Lorton, C. M., Ui Dhuibhir, P. M., O’Donoghue, N. C., O’Connor, B., Walsh, T. D.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 255 KB

english, 2017

26

Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations

Böger, C., Krüger, S., Behrens, H. M., Bock, S., Haag, J., Kalthoff, H., Röcken, C.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 824 KB

english, 2017

27

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Bleiberg, H., Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J. Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A. K., Mitchell, E., Schmoll, H.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 185 KB

english, 2017

28

Acquiring evidence for precision prostate cancer care

Mateo, J., Carreira, S., de Bono, J. S.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 58 KB

english, 2017

29

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States

Mahal, B. A., Chen, Y.-W., Muralidhar, V., Mahal, A. R., Choueiri, T. K., Hoffman, K. E., Hu, J. C., Sweeney, C. J., Yu, J. B., Feng, F. Y., Kim, S. P., Beard, C. J., Martin, N. E., Trinh, Q.-D., Nguy

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 364 KB

english, 2017

30

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015

Vivot, A., Jacot, J., Zeitoun, J.-D., Ravaud, P., Crequit, P., Porcher, R.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 200 KB

english, 2017

31

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

Dréno, B., Ribas, A., Larkin, J., Ascierto, P. A., Hauschild, A., Thomas, L., Grob, J.-J., Koralek, D. O., Rooney, I., Hsu, J. J., McKenna, E. F., McArthur, G. A.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 434 KB

english, 2017

32

MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk

Zhang, L., Ye, Y., Tu, H., Hildebrandt, M. A., Zhao, L., Heymach, J. V., Roth, J. A., Wu, X.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 218 KB

english, 2017

33

Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient

Romero-Laorden, N., Piñeiro-Yañez, E., Gutierrez-Pecharroman, A., Pacheco, M. I., Calvo, E., Al-Shahrour, F., Castro, E., Olmos, D.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 183 KB

english, 2017

34

A step towards the harmonization of clinical trials inform consent forms

Remon, J., Ferté, C.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 67 KB

english, 2017

35

Reply to ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by J. Furlanetto et al.

Daly, L. E., Power, D. G., Ryan, A. M.

Journal:

Annals of Oncology

Year:

2017

File:

PDF, 45 KB

2017

36

Reply to ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by J. Furlanetto et al.

Daly, L. E., Power, D. G., Ryan, A. M.

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 45 KB

english, 2017

37

Editorial Board

Journal:

Annals of Oncology

Year:

2017

File:

PDF, 108 KB

2017

Volume 28; Issue 5

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

The role of AR polyQ tract in male breast carcinoma: lesson from an SBMA case

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial

CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

Data resources for the identification and interpretation of actionable mutations by clinicians

Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma

Modeling individual and relative accuracy of screening tools in geriatric oncology

Intratumoral heterogeneity in gastric cancer: a new challenge to face

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

European cancer mortality predictions for the year 2017, with focus on lung cancer

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?

Immunotherapy and epithelial ovarian cancer: a double-edged sword?

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape

HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

Subjective and objective taste and smell changes in cancer

Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Acquiring evidence for precision prostate cancer care

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk

Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient

A step towards the harmonization of clinical trials inform consent forms

Reply to ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by J. Furlanetto et al.

Reply to ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by J. Furlanetto et al.

Table of Contents

Editorial Board